Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin
Open Access
- 15 November 2009
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 15 (12) , 1407-1413
- https://doi.org/10.1038/nm.2056
Abstract
In a mouse model of Huntington's disease, synaptic activation of NMDA receptors induces the formation of huntingtin-containing inclusions, rendering neurons more resistant to death in vivo and in vitro. In contrast, stimulation of extrasynaptic NMDA receptors increases neuronal vulnerability by preventing inclusion formation. Huntington's disease is caused by an expanded CAG repeat in the gene encoding huntingtin (HTT), resulting in loss of striatal and cortical neurons. Given that the gene product is widely expressed, it remains unclear why neurons are selectively targeted. Here we show the relationship between synaptic and extrasynaptic activity, inclusion formation of mutant huntingtin protein (mtHtt) and neuronal survival. Synaptic N-methyl-D-aspartate–type glutamate receptor (NMDAR) activity induces mtHtt inclusions via a T complex-1 (TCP-1) ring complex (TRiC)-dependent mechanism, rendering neurons more resistant to mtHtt-mediated cell death. In contrast, stimulation of extrasynaptic NMDARs increases the vulnerability of mtHtt-containing neurons to cell death by impairing the neuroprotective cyclic AMP response element–binding protein (CREB)–peroxisome proliferator–activated receptor-γ coactivator-1α (PGC-1α) cascade and increasing the level of the small guanine nucleotide–binding protein Rhes, which is known to sumoylate and disaggregate mtHtt. Treatment of transgenic mice expressing a yeast artificial chromosome containing 128 CAG repeats (YAC128) with low-dose memantine blocks extrasynaptic (but not synaptic) NMDARs and ameliorates neuropathological and behavioral manifestations. By contrast, high-dose memantine, which blocks both extrasynaptic and synaptic NMDAR activity, decreases neuronal inclusions and worsens these outcomes. Our findings offer a rational therapeutic approach for protecting susceptible neurons in Huntington's disease.Keywords
This publication has 43 references indexed in Scilit:
- Rhes, a Striatal Specific Protein, Mediates Mutant-Huntingtin CytotoxicityScience, 2009
- Cytoplasmic Inclusions of Htt Exon1 Containing an Expanded Polyglutamine Tract Suppress Execution of Apoptosis in Sympathetic NeuronsJournal of Neuroscience, 2008
- Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation stateNature Cell Biology, 2006
- The chaperonin TRiC controls polyglutamine aggregation and toxicity through subunit-specific interactionsNature Cell Biology, 2006
- Chaperonin TRiC Promotes the Assembly of polyQ Expansion Proteins into Nontoxic OligomersMolecular Cell, 2006
- Preconditioning Doses of NMDA Promote Neuroprotection by Enhancing Neuronal ExcitabilityJournal of Neuroscience, 2006
- Paradigm shift in neuroprotection by NMDA receptor blockade: Memantine and beyondNature Reviews Drug Discovery, 2006
- Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal deathNature, 2004
- The Hsp70 and TRiC/CCT Chaperone Systems Cooperate In Vivo To Assemble the Von Hippel-Lindau Tumor Suppressor ComplexMolecular and Cellular Biology, 2003
- Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in BrainScience, 1997